Ratings by BofA Securities (Lyanne Harrison)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 10/20/2022 | ResMed | RMD | Upgrade | Buy (Neutral) |
215.30 (221.32) |
2.8% | Details | |
| 7/25/2022 | ResMed | RMD | Maintain | Neutral (N/A) |
|
Details | ||
| 6/15/2022 | ResMed | RMD | Maintain | Neutral (N/A) |
|
Details | ||
| 4/29/2022 | ResMed | RMD | Maintain | Neutral (N/A) |
|
Details | ||
| 1/24/2022 | ResMed | RMD | Upgrade | Neutral (Underperform) |
235.16 (221.32) |
-5.89% | Details | |
| 10/29/2021 | ResMed | RMD | Maintain | Underperform (N/A) |
|
Details | ||
| 10/26/2021 | ResMed | RMD | Maintain | Underperform (N/A) |
|
Details | ||
| 8/27/2021 | Avita Medical Ltd. | RCEL | Maintain | Buy (N/A) |
|
Details | ||
| 8/6/2021 | ResMed | RMD | Maintain | Underperform (N/A) |
|
Details | ||
| 6/24/2021 | Avita Medical Ltd. | RCEL | Maintain | Buy (N/A) |
|
Details | ||
| 6/16/2021 | ResMed | RMD | Downgrade | Underperform (Neutral) |
236.46 (221.32) |
-6.4% | Details | |
| 8/3/2020 | ResMed | RMD | Downgrade | Neutral (Buy) |
202.51 (236.46) |
16.76% | Details | |
| 10/25/2019 | ResMed | RMD | Maintain | Buy (N/A) |
|
Details |
